No Data
Heyuan Biotech: 2024 Annual Results Report Announcement
2024 Annual Results Express Announcement
He Yuan Biotechnology (688238.SH): Net loss of 0.325 billion yuan in 2024.
On February 26, Gelonghui reported that Heyuan Bio (688238.SH) announced its annual performance report for 2024. During the reporting period, the company achieved revenue of 0.247 billion yuan, an increase of 20.60% compared to the same period last year; it reported a net income attributable to shareholders of the parent company of -0.325 billion yuan; and a net income attributable to shareholders of the parent company, excluding non-recurring gains and losses, of -0.336 billion yuan.
Huan Yuan Biological (688238.SH): Currently, collaboration has been established with companies related to AI technology.
On February 7, Gelonghui reported that Heyuan Biotechnology (688238.SH) stated on the interactive platform that the fluctuation in stock price is influenced by multiple factors. The company places great importance on Market Cap management, currently focusing on its main Business, continuously improving the quality of Operation management, optimizing corporate compliance governance, strengthening investor relations, and working hard to enhance the company's performance to reward investors. The company has released a notice regarding the proposal of its controlling Shareholder, actual controller, Director, and General Manager to repurchase company shares, and will fulfill disclosure obligations in a timely manner according to regulatory requirements. The company has always paid close attention to the development of AI technology.
The actual controller of Heyuan Biotech (688238.SH) proposed that the company spend 0.05 billion to 0.1 billion yuan to repurchase shares.
Heyuan Biological (688238.SH) announced that the company received a notification from its controlling Shareholder on January 23, 2025...
Heyuan Biological (688238.SH): Chairman and General Manager Pan Oufeng proposed to repurchase the company's shares.
On January 23, Gelonghui reported that Heyuan Biotechnology (Shanghai) Co., Ltd. (688238.SH) announced that it had received a letter from Mr. Pan Oudong, the company's controlling shareholder, actual controller, Director, and General Manager, regarding the proposal to repurchase shares of the company on January 23, 2025. Mr. Pan Oudong proposed that the company repurchase a portion of its issued ordinary shares (A-shares) through centralized bidding transactions on the Shanghai Stock Exchange trading system. The total amount of funds for this repurchase will not be less than RMB 50 million (inclusive) and not more than RMB 100 million (inclusive).
Is Obio Technology (Shanghai) (SHSE:688238) Using Too Much Debt?
